Organon announces acquisition of Kadmus Pharmaceuticals' FAAH inhibitor technology
28-Jun-2007 -
N.V. Organon, the human healthcare business unit of Akzo Nobel, announced an asset purchase of the Fatty Acid Amide Hydrolase (FAAH) technology from Kadmus Pharmaceuticals, Inc. in Irvine CA (USA).
Under the asset purchase agreement, Organon has acquired world-wide rights and control of all ...
Akzo Nobel
anxiety
depressions
+7